Breaking News
A study that investigated the effects of tattoo ink on the body has found that the ink travels through the lymphatic system and kills immune cells, as well as alters the effects of some vaccines.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval of VOYXACT (sibeprenlimab-szsi) for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.
Researchers at Ben-Gurion University of the Negev in Israel have discovered a way to destroy harmful “senescent” cells that accumulate with age and increase the kind of tissue damage and inflammation that slowly causes life to end.
BioTrending
- By Keith Berman, MPH, MBA
Therapeutic plasma exchange may improve outcomes for patients diagnosed with sepsis or septic shock, but funding is needed to conduct needed clinical trials.
- By Trudie Mitschang
As chronic disease and aging populations drive healthcare costs higher, value-based care offers a sustainable path forward — rewarding providers for better outcomes, improved patient experiences and greater cost-efficiency.
- By Diane L.M. Cook
With a pending shortage of cardiologists, there is a growing need for remote cardiac monitoring, and now, three FDA-cleared products are transforming how this care is provided.
- By Lee Warren
The use of AI is growing at a brisk rate as healthcare professionals realize its potential as an indispensable partner in treating patients.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
